Back to top
more

SpringWorks Therapeutics (SWTX)

(Delayed Data from NSDQ)

$45.53 USD

45.53
898,993

+1.33 (3.01%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

by Zacks Equity Research

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why

by Zacks Equity Research

SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

by Zacks Equity Research

The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.

SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data

by Zacks Equity Research

SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why You Should Consider Investing in JAZZ Stock Now

by Zacks Equity Research

JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

by Zacks Equity Research

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

by Zacks Equity Research

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research

With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.

SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.

Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies

by Zacks Equity Research

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

New Strong Sell Stocks for August 13th

by Zacks Equity Research

LASR, TWLO, SWTX, FSLY, and UUUU have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2021

Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.

New Strong Sell Stocks for June 10th

by Zacks Equity Research

AREC, RNLSY, and SWTX have been added to the Zacks Rank #5 (Strong Sell) List on June 10, 2021.

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag

by Zacks Equity Research

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study

by Zacks Equity Research

SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod

by Zacks Equity Research

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the third quarter of 2020.

SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

SpringWorks Inks Deal With Pfizer for Nirogacestat Combo

by Zacks Equity Research

SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.

SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.